基因工程工具市场 - 全球产业规模、份额、趋势、机会及预测（按类型、治疗领域、最终用户、地区和竞争格局划分，2021-2031年）

全球基因工程工具市场预计将从2025年的220.9亿美元成长到2031年的285.7亿美元，复合年增长率（CAGR）为4.38%。这些工具包括专用平台、酵素和试剂，例如限制性内切酶和CRISPR-Cas9，用于改造基因组材料，应用于科研、农业和医疗保健领域。市场成长要素：需要精准基因治疗的遗传疾病发病率不断上升，以及全球对基因改造作物的需求日益增长，以增强粮食安全。此外，对基因组研究基础设施和合成生物学的大量投资为这些技术奠定了坚实的基础，确保了其在产业波动中的稳定性。

然而，该行业面临着许多挑战，包括由于严格的监管要求和与脱靶效应相关的伦理问题，导致新治疗方法核准流程漫长。儘管研发活动十分活跃，但这种复杂的合规环境仍对商业化构成重大障碍。根据美国基因与细胞治疗学会 (ASGCT) 的报告，到 2025 年，全球开发平臺仍将保持强劲势头，届时将有超过 3200 项 RNA、细胞和基因疗法的临床试验正在进行中。

市场驱动因素

基因编辑平台，特别是CRISPR-Cas9技术的快速发展，是推动基因编辑产业成长的关键催化剂。 CRISPR-Cas9技术已从实验室概念发展成为临床验证的治疗方法。这项进步迫使工具供应商开发高度精密、精准的试剂和自动化系统，以满足人体应用所需的严格标准。精准医疗运动将基因编辑工具的品质与基因疗法的商业性成功直接连结起来。例如，2024年1月，Vertex Pharmaceuticals宣布其首个用于治疗输血依赖型β-地中海贫血的CRISPR/Cas9基因编辑疗法CASGEVY已获得美国FDA核准。这是一个里程碑式的成就，展现了这些现代基因编辑技术的成熟度与效用。

同时，生物技术公司和基因组学研究领域私人和公共资金的大幅成长推动了先进工程设备的购买。大规模的资本注入使新兴生物製药公司能够扩展其研发能力，从而增加了从设备製造商采购硬体和耗材的数量。这种融资动能不仅限于Start-Ups，也延伸至支持新兴平台技术的大型企业联合组织。 2025年3月，《Fierce Biotech》报道称，Xaira Therapeutics已筹集创纪录的10亿美元资金，用于推进人工智慧主导的药物发现。这种强劲的投资环境正在支撑供应链并带来实际成果。再生医学联盟在2025年指出，上年度共有9种新产品核可，显示市场对检验的工具的需求持续强劲。

市场挑战

全球基因工程工具市场面临许多挑战，包括严格的法规结构和关于脱靶效应的伦理担忧。这些合规要求迫使研发人员进行广泛而漫长的安全测试，以证明基因编辑干预不会导致意外的基因组改变。因此，治疗候选药物从临床研究到商业化生产的进程有显着延迟。这种延误直接阻碍了工具供应商的市场扩张，因为从小规模研究试剂到大规模商业采购的过渡被持续推迟。

监管瓶颈的影响体现在活跃开发平臺与实际上市产品之间的巨大差距。根据再生医学联盟统计，2024年全球仅9种新产品获得核准。如此有限的商业审批数量限制了大规模基因工程产品的潜在市场。因此，随着业界努力应对将这些技术应用于患者的复杂核准流程，工具製造商的先进平台收入成长正在放缓。

市场趋势

利用人工智慧优化引导RNA设计，从根本上改变了基因工程工具的开发方式，最大限度地减少了试验造成的延误。开发人员正在使用平台模型以惊人的速度预测分子交互作用，从而能够生产具有高度特异性且脱靶风险较低的基因编辑工具。这项技术进步直接支持了复杂基因组修饰所需的高精度试剂的生成。例如，NVIDIA于2025年2月宣布，其基于约9兆个碱基对训练的平台模型「Evo 2」能够准确预测基因序列以及蛋白质的功能和结构。

同时，基因编辑技术在气候适应农业领域的进步，正催生一个专注于多功能、高通量植物育种系统的市场区隔。与人类治疗不同，该领域需要广泛的编辑功能，以提高不同地区作物对环境压力的耐受性。这一趋势包括将专有的编辑架构授权给全球研究团队，以加速改良主粮作物的推广应用。例如，2025年6月，Pairwise公司宣布将其Fulcrum平台授权给国际玉米和甘薯改良中心（CIMMYT），以加速20个国家的性状开发。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球基因工程工具市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（基因组规模编辑工具、基因组规模工程工具）
  • 依治疗领域（镰状细胞疾病、心臟病、糖尿病、阿兹海默症、肥胖、其他）
  • 依最终用户（生技/製药公司、学术/研究机构、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美基因工程工具市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

7. 欧洲基因工程工具市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区基因工程工具市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲基因工程工具市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲基因工程工具市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球基因工程工具市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Thermo Fisher Scientific Inc.
• Lonza
• Cibus
• Recombinetics Inc.
• Sangamo
• Merck KGaA
• Precision Biosciences
• OriGene Technologies Inc.
• Intellia Therapeutics Inc.
• Caribou Biosciences Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Genetic Engineering Tool Market is projected to expand from USD 22.09 Billion in 2025 to USD 28.57 Billion by 2031, reflecting a CAGR of 4.38%. These tools consist of specialized platforms, enzymes, and reagents-such as restriction nucleases and CRISPR-Cas9-used to alter genomic material for applications in research, agriculture, and medicine. The market is chiefly driven by the rising incidence of genetic diseases, which demands precise gene therapies, and the growing global need for genetically modified crops to bolster food security. Furthermore, significant investments in genomic research infrastructure and synthetic biology provide a solid foundation for these technologies, offering stability amidst industry fluctuations.

Nevertheless, the industry encounters substantial obstacles due to rigorous regulatory requirements and ethical issues related to off-target effects, which frequently extend the approval timelines for new treatments. This intricate compliance environment imposes significant barriers to commercialization, even with high levels of research engagement. As reported by the American Society of Gene & Cell Therapy, the global development pipeline remained strong in 2025, featuring over 3,200 active clinical trials for RNA, cell, and gene therapies.

Market Driver

A primary catalyst for growth is the rapid technological evolution of genome editing platforms, specifically the progression of CRISPR-Cas9 from a laboratory concept to a clinically proven therapeutic method. This advancement forces tool providers to engineer highly refined, high-fidelity reagents and automated systems that satisfy the strict standards necessary for human use. The trend toward precision medicine establishes a direct connection between the quality of engineering tools and the commercial success of gene therapies. For example, Vertex Pharmaceuticals announced in January 2024 that the US FDA approved CASGEVY, the first CRISPR/Cas9 gene-edited therapy for transfusion-dependent beta-thalassemia, a milestone that validates the maturity and utility of these modern editing suites.

Concurrently, a significant increase in private and public funding for biotechnology ventures and genomic research is driving the acquisition of advanced engineering instrumentation. Large capital infusions allow emerging biopharmaceutical firms to expand their R&D capabilities, thereby boosting the purchase volume of hardware and consumables from tool manufacturers. This financial momentum extends beyond startups to major syndicates backing new platform technologies; Fierce Biotech reported in March 2025 that Xaira Therapeutics raised a record $1 billion to further AI-led drug discovery. Such a strong investment landscape supports the supply chain and results in tangible outcomes, with the Alliance for Regenerative Medicine noting in 2025 that the sector saw nine new product approvals the previous year, maintaining demand for validated tools.

Market Challenge

The Global Genetic Engineering Tool Market faces a formidable barrier in the form of strict regulatory frameworks and ethical issues regarding off-target effects. These compliance demands compel developers to undertake extensive and prolonged safety studies to demonstrate that gene-editing interventions do not induce unintended genomic changes. As a result, the progression of therapeutic candidates from clinical research to commercial manufacturing faces significant delays. This slowdown directly impedes market expansion for tool providers, as the expected transition from low-volume research reagent use to high-volume commercial procurement is continually pushed back.

The consequences of this regulatory bottleneck are highlighted by the gap between the active development pipeline and actual market launches. According to the Alliance for Regenerative Medicine, the sector managed only nine new product approvals globally in 2024. This restricted number of commercial authorizations limits the addressable market for large-scale genetic engineering supplies. Consequently, tool manufacturers experience slower revenue growth from their advanced platforms, as the industry grapples with navigating the intricate approval processes necessary to deliver these technologies to patients.

Market Trends

The incorporation of artificial intelligence to optimize guide RNA design is fundamentally transforming the creation of genetic engineering tools by minimizing trial-and-error delays. Developers are utilizing foundation models to predict molecular interactions with exceptional speed, enabling the production of highly specific editors that reduce off-target risks. This technological advancement directly supports the generation of high-fidelity reagents needed for complex genomic modifications. For instance, NVIDIA announced in February 2025 that its Evo 2 foundation model, trained on nearly 9 trillion nucleotides, is now available to accurately forecast the function and form of genetic sequences and proteins.

Simultaneously, the growth of gene editing in climate-resilient agriculture is fostering a specific market segment dedicated to versatile, high-throughput plant breeding systems. In contrast to human therapeutics, this sector requires broad-spectrum editing suites that can improve crop endurance against environmental stressors in various regions. This trend involves licensing proprietary editing architectures to global research groups to speed up the deployment of enhanced staple crops. As an example, Pairwise announced in June 2025 that it licensed its Fulcrum platform to CIMMYT to accelerate trait development across 20 countries.

Key Market Players

• Thermo Fisher Scientific Inc.
• Lonza
• Cibus
• Recombinetics Inc.
• Sangamo
• Merck KGaA
• Precision Biosciences
• OriGene Technologies Inc.
• Intellia Therapeutics Inc.
• Caribou Biosciences Inc.

Report Scope

In this report, the Global Genetic Engineering Tool Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genetic Engineering Tool Market, By Type

• Genome Scale Editing Tools
• Genome Scale Engineering Tools

Genetic Engineering Tool Market, By Therapeutic Area

• Sickle Cell Disease
• Heart Disease
• Diabetes
• Alzheimer's Disease
• Obesity
• Others

Genetic Engineering Tool Market, By End User

• Biotechnology & Pharmaceutical Companies
• Academic & Research Institutions
• Others

Genetic Engineering Tool Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Genetic Engineering Tool Market.

Available Customizations:

Global Genetic Engineering Tool Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Genetic Engineering Tool Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Genome Scale Editing Tools, Genome Scale Engineering Tools)
  • 5.2.2. By Therapeutic Area (Sickle Cell Disease, Heart Disease, Diabetes, Alzheimer's Disease, Obesity, Others)
  • 5.2.3. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Institutions, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Genetic Engineering Tool Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Therapeutic Area
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Genetic Engineering Tool Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Therapeutic Area
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Genetic Engineering Tool Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Therapeutic Area
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Genetic Engineering Tool Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Therapeutic Area
      • 6.3.3.2.3. By End User

7. Europe Genetic Engineering Tool Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Therapeutic Area
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Genetic Engineering Tool Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Therapeutic Area
      • 7.3.1.2.3. By End User
  • 7.3.2. France Genetic Engineering Tool Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Therapeutic Area
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Genetic Engineering Tool Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Therapeutic Area
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Genetic Engineering Tool Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Therapeutic Area
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Genetic Engineering Tool Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Therapeutic Area
      • 7.3.5.2.3. By End User

8. Asia Pacific Genetic Engineering Tool Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Therapeutic Area
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Genetic Engineering Tool Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Therapeutic Area
      • 8.3.1.2.3. By End User
  • 8.3.2. India Genetic Engineering Tool Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Therapeutic Area
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Genetic Engineering Tool Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Therapeutic Area
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Genetic Engineering Tool Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Therapeutic Area
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Genetic Engineering Tool Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Therapeutic Area
      • 8.3.5.2.3. By End User

9. Middle East & Africa Genetic Engineering Tool Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Therapeutic Area
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Genetic Engineering Tool Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Therapeutic Area
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Genetic Engineering Tool Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Therapeutic Area
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Genetic Engineering Tool Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Therapeutic Area
      • 9.3.3.2.3. By End User

10. South America Genetic Engineering Tool Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Therapeutic Area
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Genetic Engineering Tool Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Therapeutic Area
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Genetic Engineering Tool Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Therapeutic Area
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Genetic Engineering Tool Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Therapeutic Area
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Genetic Engineering Tool Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Lonza
• 15.3. Cibus
• 15.4. Recombinetics Inc.
• 15.5. Sangamo
• 15.6. Merck KGaA
• 15.7. Precision Biosciences
• 15.8. OriGene Technologies Inc.
• 15.9. Intellia Therapeutics Inc.
• 15.10. Caribou Biosciences Inc.

16. Strategic Recommendations

17. About Us & Disclaimer